Robert F. Kennedy, Jr. and President-elect Donald Trump on Oct. 23, 2024 (Alex Brandon/AP Images)
November 22, 2024 11:25 AM EST
Pharma

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Ayisha Sharma

News Reporter

Pres­i­dent-elect Don­ald Trump and Robert Kennedy, Jr. — his pick to head up the De­part­ment of Health and Hu­man Ser­vices — were hot top­ics at the Jef­feries …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

Ex­clu­sive: In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el

At least sev­en drug­mak­ers say they will par­tic­i­pate in round two of IRA ne­go­ti­a­tions 

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times